An Independent Data Monitoring Committee (IDMC) recommended stopping enrollment in TAHOE due to shorter overall survival in the Rova-T arm compared with the topotecan control arm.
Every value below carries the sentence it was read from.
460 sources stand behind the page.
Field
Value
Cited text
Known as
Topotecan
“One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine,...” NCT06861244 ↗430
“Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on...” NCT04421547 ↗
“Study treatment in the arm A is left to the investigator appreciations. This may include immune checkpoint inhibitors, docetaxel, topotecan for primary lung tumors, and FOLFOX,...” NCT06937905 ↗
“Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:
* Liposomal Doxorubicin;
* Docetaxel;
*...” NCT03949283 ↗
“Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at...” NCT00739830 ↗
“Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine.” NCT02282020 ↗
“Patients will recieve 3 cycles of carboplatin and gemcitabine followed by 3 cycles of taxol and carboplatin and then three cycles of adriamycin and topotecan.” NCT00157560 ↗
“The possible choices as defined by the protocol:
* Paclitaxel
* Gemcitabine
* Pegylated liposomal doxorubicin (PLD)
* Topotecan” NCT07546500 ↗
“Topotecan-Monotherapy Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Therapy in Patients With Recurrent Ovarian Cancer” NCT00312988 ↗
“Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes...” NCT00826891 ↗9
“This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people...” NCT00316186 ↗
“Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With Negative or Unknown...” NCT01690598 ↗
“A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix” NCT00087126 ↗
“The purpose of this study is to find out if giving oral HYCAMTIN to patients with relapsed small cell lung cancer benefits them.” NCT00276276 ↗
“The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.” NCT00267488 ↗
“A Pilot Study Of Hycamtin (Topotecan) And Thalomid (Thalidomide) In Patients With Recurrent Malignant Gliomas” NCT00014443 ↗
“Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg” NCT00918320 ↗
ChEMBL registry synonym — accepted as the source's own labelCHEMBL84 ↗
Known as
nogitecan hydrochloride
“METHODS: Patients were randomized 1:1 to tisotumab vedotin or investigator-choice chemotherapy (topotecan [nogitecan hydrochloride], vinorelbine, gemcitabine, irinotecan, or...” PMID 41644383 ↗Dec 2025
Known as
NSC #609699
“A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent...” NCT00276796 ↗6
“Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).” NCT00002625 ↗
“A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix” NCT00087126 ↗
“Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer” NCT00005029 ↗
“A Phase II Study of Continuous 21 Day Infusion of Topotecan (NSC # 609699) in Children With Relapsed Solid Tumors” NCT00003745 ↗
“Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).” NCT00002625 ↗
Known as
Topotecan (as hydrochloride)
ChEMBL registry synonym — accepted as the source's own labelCHEMBL84 ↗
ChEMBL registry synonym — accepted as the source's own labelCHEMBL84 ↗
Known as
Topotecan eagle
ChEMBL registry synonym — accepted as the source's own labelCHEMBL84 ↗
Known as
Topotecan HCl
“Participants will receive topotecan HCl 1.25 mg per square meter per day, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.” NCT01840943 ↗
Known as
Topotecan hospira
ChEMBL registry synonym — accepted as the source's own labelCHEMBL84 ↗
Known as
Topotecan Hydrochloride
“This phase II trial studies how well berzosertib (M6620) works when given in combination with topotecan hydrochloride (topotecan) compared with topotecan alone in treating...” NCT03896503 ↗55
“Topotecan hydrochloride capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is, 21 days (3 weeks) as a course of treatment, a total of 6...” NCT05736952 ↗
“Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).” NCT00002625 ↗
“PURPOSE: To estimate antitumor activity and toxicity of weekly topotecan hydrochloride in patients with persistent or recurrent cervical carcinoma who failed prior treatment.” PMID 19726073 ↗Sep 2009
“Arm II (experimental): Patients receive N8 chemotherapy comprising topotecan hydrochloride IV continuously over 168 hours and cyclophosphamide IV over 1 hour on days 1-7” NCT00410631 ↗
“Patients receive topotecan hydrochloride IV, cyclophosphamide IV, and carboplatin IV over 8 hours on days -6 to -3.” NCT00652691 ↗
“Patients receive cyclophosphamide IV over 30 minutes and topotecan hydrochloride IV over 30 minutes on days 1-5” NCT00567567 ↗
“topotecan (topotecan hydrochloride) 0.6 mg/m\^2 administered IV once daily on days 1 to 5 of each cycle” NCT01266447 ↗
“topotecan hydrochloride in treating patients with relapsed or refractory small cell lung cancer” NCT00521144 ↗
“Patients receive escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8” NCT00541359 ↗
“Patients receive oral topotecan hydrochloride on days 1, 8, and 15 and carboplatin IV on day 1.” NCT00807079 ↗
ChEMBL registry synonym — accepted as the source's own labelCHEMBL84 ↗
Known as
Topotecane
ChEMBL registry synonym — accepted as the source's own labelCHEMBL84 ↗
Known as
TPT
“This clinical trial is designed to explore the hypothesis that chronic administration of topotecan (TPT) inhibits Hypoxia Inducible factor 1alpha (HIF-1alpha) expression and...” NCT00117013 ↗3
“daily 30-minute infusions of topotecan (TPT) for up to 12 consecutive days” PMID 11896112 ↗Mar 2002
“To test the safety of the combination of ABT-888 and Topotecan (TPT)” NCT00553189 ↗